As of December 31, 2022, U.S. Stem Cell, Inc. carries a market capitalization of 3.05M, placing it among publicly traded companies globally. Its enterprise value stands at 11.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.05M |
| Enterprise Value | 11.99M |
As of December 31, 2022, U.S. Stem Cell, Inc. has 634.40M shares outstanding.
| Shares Outstanding | 634.40M |
These figures are as of December 31, 2022. The price-to-sales ratio is 34.59, and the price-to-book ratio stands at -0.21.
| PS Ratio | 34.59 |
| PB Ratio | -0.21 |
| P/TBV Ratio | -0.21 |
| P/FCF Ratio | -9.31 |
| P/OCF Ratio | -9.31 |
These figures are as of December 31, 2022. The EV/Sales ratio of 146.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 11.99M versus a market cap of 3.05M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 146.09 |
As of December 31, 2022, U.S. Stem Cell, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -60.68, indicating conservative leverage, while an interest coverage ratio of -2.49 demonstrates limited ability to service its debt obligations.
| Debt / Equity | -60.68 |
| Debt / EBITDA | -5.20 |
| Interest Coverage | -2.49 |
These figures cover the twelve months ended December 31, 2022. Return on assets (ROA) is negative at -4,801.73, reflecting losses generated across the asset base. The company generates approximately 20,512.25 in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 34.62 indicates how many times U.S. Stem Cell, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -4,801.73 |
| Revenue Per Employee | 20,512.25 |
| Employee Count | 4.00 |
| Inventory Turnover | 34.62 |
Over the twelve months ended December 31, 2022, U.S. Stem Cell, Inc. generated 82,049.00 in revenue and converted that into -2.86M in net income, yielding earnings per share of 0.00. EBITDA reached -1.72M, while operating income came in at -1.72M.
| Revenue | 82,049.00 |
| Gross Profit | 58,282.00 |
| Operating Income | -1.72M |
| Pretax Income | -2.86M |
| Net Income | -2.86M |
| EBITDA | -1.72M |
| EBIT | -1.72M |
As of December 31, 2022, U.S. Stem Cell, Inc. holds 5,133.00 in cash and equivalents against 8.95M in total debt, resulting in a net debt position of 8.94M. Total book value stands at -14.75M, with working capital of -14.01M providing operational flexibility.
| Cash & Cash Equivalents | 5,133.00 |
| Total Debt | 8.95M |
| Net Debt | 8.94M |
| Equity (Book Value) | -14.75M |
| Book Value Per Share | -0.02 |
| Working Capital | -14.01M |
U.S. Stem Cell, Inc. produced -304,852.00 in operating cash flow over the twelve months ended December 31, 2022.
| Operating Cash Flow | -304,852.00 |
| Free Cash Flow | -304,852.00 |
Over the twelve months ended December 31, 2022, U.S. Stem Cell, Inc. posted a gross margin of 71.03, reflecting its pricing power and cost economics. The operating margin of -2,096.90 and net profit margin of -3,483.21 provide insight into operational efficiency.
| Gross Margin | 71.03 |
| Operating Margin | -2,096.90 |
| Pretax Margin | -3,483.21 |
| Profit Margin | -3,483.21 |
| EBITDA Margin | -2,096.90 |
These figures cover the twelve months ended December 31, 2022. Free cash flow yield is negative at -10.74: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.89, meaning U.S. Stem Cell, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -8.89 |
| FCF Yield | -10.74 |
U.S. Stem Cell, Inc.'s most recent stock split took place on November 4, 2015 with a 1000:1 split ratio.
| Last Split Date | 11/4/2015 |
| Split Ratio | 1000:1 |
As of December 31, 2022, U.S. Stem Cell, Inc. has an Altman Z-Score of -3,261.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3,261.71 |